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ABSTRACT
MODULATION OF CELL DEATH SIGNALING AND CELL
PROLIFERATION BY THE INTERACTION OF
HOMOSERINE LACTONES AND PARAOXONASE 2
Aaron Mackallan Neely
March, 29th, 2016
Pseudomonas aeruginosa produces N-(3-oxododecanoyl)-homoserine lactone
(C12) as a quorum-sensing molecule that functions to facilitate bacteria-bacteria
communication. C12 has also been reported to affect many aspects of human
host cell physiology, including evoking cell death in various types of cells.
However, the signaling pathway(s) leading to C12-triggerred cell death remains
unclear. To clarify cell death signaling induced by C12, we examined mouse
embryonic fibroblasts (MEFs) deficient in one or more caspases. Our data
indicate that, unlike most apoptotic inducers, C12 evokes a novel form of
apoptosis in cells, probably through the direct induction of mitochondrial
membrane permeabilization. Previous studies indicate that C12 requires the
lactonase/arylesterase paraoxonase 2 (PON2) to exert its cytotoxicity on MEFs.
PON2 is known to function as a lactonase to cleave C12. We found that PON2
was overexpressed in tissues from non-small cell lung carcinoma (NSCLC)
patients and oncogenically transformed human bronchia/tracheal epithelial
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(NHBE) cells. Reducing PON2 expression in NSCLC cell lines as well as several
non-transformed cell lines rendered them resistant to C12. However, PON2
expression is only important for the proliferation of NSCLC cell but not that of
their untransformed counterparts, indicating that PON2 mediates apoptosis
independently of its function to modulate cell proliferation. Overall, our results
reveal a unique mitochondrial apoptotic signaling pathway triggered by
C12/PON2 interaction and PON2 plays distinct roles in apoptosis signaling and
cell proliferation.
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CHAPTER 1: INTRODUCTION
Tissue differentiation and homeostasis are tightly regulated by the BcL-2
regulated cellular suicide program, apoptosis (2,3). Many human tumor cells
acquire resistance to conventional chemotherapeutic drugs that depend on BcL-2
proteins. These neoplastic cells have been found to have an increased ratio of
anti-apoptotic to pro-apoptotic Bcl-2 proteins. Thus, the discovery of novel drugs
that are capable of overcoming apparent tumor cell BcL-2 protein dependent
resistance to cell death is a major challenge. A promising anti-tumor approach is
the identification of small molecules (as well as their cellular targets) that
preferentially trigger tumor cell apoptosis, independent of tumor cell Bcl-2 protein
profile (4,5). While several candidate compounds have been identified, most if
not all of these drugs could only induce apoptosis independent of either antiapoptotic or pro-apoptotic Bcl-2 proteins; but not both (5-7). Conversely, the
quorum-sensing molecule N-(3-oxododecanoyl)-homoserine lactone (C12)
preferentially induces transformed cell apoptosis in vitro and inhibits transplanted
tumor growth in vivo independent of both anti- and pro-apoptotic Bcl-2 proteins;
thereby making it an ideal candidate drug. Our preliminary data indicates that
C12 triggers Bcl-2 protein-independent apoptosis, likely mediated by
Paraoxonase 2 (Pon2). PON2 is known to function as a lactonase to cleave C12.
Previous studies indicate that C12 requires the lactonase / arylesterase PON2 to
exert its cytotoxicity (8,9).
1

1.1. Programmed cell death-Apoptosis
The word Apoptosis derives from Greek origin meaning “dropping off or falling
off,” and initially referred to the process by which leaves fell from trees or petals
from flowers. Apoptosis is a biological phenomenon that consists of a
programmed sequence of biochemical events that culminate in the selective
elimination of damaged, infected and potentially neoplastic cells from the bodies
of multicellular organisms (10,11). Apoptosis is one of the most ubiquitously
employed mechanisms by which the body disposes of cell debris or damaged
cells without eliciting localized inflammation; due to leakage of cellular
contents(12). This mode of cell death is a vital component of normal tissue
development, disease progression and maintenance of tissue homeostasis.
Additionally, it serves as a means of defense against the development and
advancement of cancer (13). The biochemical events that result in the
occurrence of Apoptosis also elicit a large number of morphological changes in
cells including cell shrinkage, blebbing of the membrane, condensation and
fragmentation of nuclear material and the formation of apoptotic bodies.

1.2. Regulation of apoptosis
Apoptosis is under stringent genetic control and can be activated by stimuli from
multiple sources. It is initiated in response to specific developmental signals or in
the presence of various stimuli including the reduction of essential growth factors,
the activation of Tumor Necrosis Factor receptors (TNFR), DNA damage, loss of
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cellular attachment, decreases in the local concentration of tissue morphogens
and major alterations in homeostatic state of the cell(14,15).
Excess or limited apoptosis can disrupt tissue homeostasis of multicellular
organisms. When apoptosis occurs more frequently than cell proliferation does,
neurodegenerative disorders are exacerbated. Further to this, the dysregulation
of apoptosis has been implicated in the ontogeny and progression of many
disease states including many cancers and neurodegenerative disorders such as
Alzheimer’s, Huntington’s and Parkinson’s diseases (16-18). Conversely,
insufficient apoptosis can precipitate cancer development and progression
(19,20). Thus, tight regulation between apoptosis and cell proliferation is
imperative for the viability of all multicellular organisms.

1.3. Biological significance of apoptosis
Apoptosis has long been recognized as a critical regulatory component of the
development process. The role of apoptosis in development has been
investigated and well established in three organisms: Nematodes
(Caenorhabditis elegans), Fruit Flies (Drosophila melanogaster) and mouse (Mus
musculus). Apoptosis has been found to drive hemaphroditic development during
embryogenesis in C. elegans and promote the completion of development in D.
melanogaster(21). Studies have indicated that the inhibition of apoptosis elicits
developmental impediments, disorders and/or death (13,22).
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In early mammalian development, apoptosis is instrumental in the formation of
synapses between neurons in the brain and the spinal cord as it facilitates the
removal of excess neurons cells(23). Additionally, Apoptosis assists in tissue
remodeling, molding and shaping of the body and organs and the
detailing/separation of extremities (fingers and toes) by the removal of excess
tissues. Inhibition or insufficient apoptotic signaling elicits malformed limbs and
digits joined by soft tissue (Figure 1.1) (1).

Figure 1.1 Apoptosis is required for proper development. (A)
Cells between the digits undergo apoptosis to facilitate proper
finger and toe formation. (B) Insufficient apoptosis elicits
malformed digits that are joined by soft tissues yielding the
persistence of interdigital web as seen in the duck (1).
Apoptosis is also vital in the removal of those cells that may have deleterious
effects on the organism. These include cells that are capable of participating in
an autoimmune response as well as virally infected; and thus cytotoxic, T cells
(24). Apoptosis facilitates the maintenance of tissue homeostasis. In the average
adult, billions of cells die daily via apoptosis and are then replaced with new cells
that originate from the body’s stem cell populations (25). Apoptosis regulates the
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constant internal environment and normal tissue homeostasis. Under healthy and
normal conditions, the rate of cell proliferation is approximately the same as the
rate of apoptosis. This paradigm is essential for ensuring the viability of
multicellular organisms. If this balance is disrupted, such that the occurrence of
cell death is more frequent than that of cell replacement, the probability of the
onset of neurodegenerative disorders is amplified. Moreover, inadequate
apoptosis may elicit cancer development (26).

1.4. The pathways of apoptosis
Apoptosis typically occurs through one of three signaling pathways, namely the
mitochondrial (intrinsic), the death receptor (extrinsic) and the mixed pathways.

1.4.1 The intrinsic pathway of apoptosis
Intracellular death signals are translocated to the mitochondria where they induce
the mitochondria dependent intrinsic pathway of apoptosis. These signals
activate the pro-apoptotic Bcl-2 proteins, which in turn lead to the formation of
permeation channels on the outer mitochondrial membrane (OMM). These
permeation channels facilitate the release of apoptogenic proteins (Diablo/Smac
and cytochrome c) from the mitochondrial inter-membrane space (IMS) into the
cytosol. Upon release into the cytosol, Diablo/Smac and cytochrome c induce a
cascade of caspase reactions that culminate in the occurrence of apoptosis(27).
Cytochrome c activates apoptotic protease factor 1 (apaf1), which promotes the
transition of procaspases to their active caspase form. Diablo/Smac promotes
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apoptosis through direct interaction with inhibitors of apoptosis proteins (IAPs),
thereby impeding their ability to inactivate caspases (Figure 1.2) (28,29).

Figure1.2. The intrinsic (mitochondrial) pathway of apoptosis.
Apoptotic stimuli; such as DNA damage, elicits p53 activation.
Activated p53 activates pro-apoptotic Bcl-2 proteins which in turn
forms permeation channels on the OMM. These permeation
channels facilitate the transport of cytochrome C and Diablo/Smac
into the cytosol. While in the cytosol, cytochrome C initiates a
caspase cascade that culminates in the occurrence of apoptosis
while Diablo/Smac interacts with IAPs impeding their ability to inhibit
caspases thereby promoting apoptosis. The figure is from Dr. Mohd
Saquib Khan at Pondicherry University.
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1.4.2 The extrinsic pathway of apoptosis
In contrast to the intrinsic apoptotic pathway, death signals for extrinsic apoptotic
pathways are initiated from the outside of the cell. Induction of the extrinsic
apoptotic pathways does not involve the mitochondria, involvement of the Bcl-2
protein family or the release of cytochrome c forms the mitochondrial IMS to the
cytosol. In this pathway, specific death ligands such as tumor necrosis factor
(TNF), Fas Ligand (FasL) or TNF-related apoptosis-inducing ligand (TRAIL)
binds to their respective specific transmembrane death receptors including FAS,
tumor necrosis factor receptor 1 (TNFR1), p75, DR4(30).

The binding of death ligands to their respective specific death receptor promotes
the collection and recruitment of the adaptor protein Fas-associated death
domain (FADD) and the inactive forms of the initiator caspases 8 and 10 (procaspases 8 and 10), thus allowing for the formation of the death-inducing
signaling complex (DISC). The DISC transports the procaspase molecules in
close proximity, thereby ensuring access for their autocatalysis and eventual
release into the cytosol (31-35). Caspase 8 or 10 will then activate the effector
caspases 3/7 in a cascade precipitated by caspase-mediated reactions that will
culminate in the occurrence of apoptosis.
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Figure 1.3. The extrinsic (death receptor) pathway of apoptosis.
Extrinsic apoptotic signaling is generated extracellularly with the
binding of death ligands to specific transmembrane death receptors.
Activation of death receptors elicit clustering and recruitment of the
adaptor molecule FADD, procaspase 8, 10 resulting in the formation of
the DISC. DISC formation activates caspase 8, 10. Caspase 8, 10 then
activates caspase 3/6/7 and leads to apoptosis. The figure is from Dr.
Mohd Saquib Khan at Pondicherry University.
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1.4.3 The mixed pathway of apoptosis
There exist certain instances where the induction of apoptotic signaling cascades
from external sources can also elicit the activation of both intrinsic and extrinsic
apoptotic pathways. This phenomenon is known as the mixed apoptotic pathway
and entails death stimuli that are generated extracellularly causing the activation
of pro caspase 8, pro caspase 10, and formation of the DISC; in the same
manner as observed in the extrinsic apoptotic pathway. The DISC formation will
ultimately lead to autocatalysis and the eventual activation of caspase 8 and 10
(31-35). When caspase 8 is activated, it can enter one of two routes: (i) it can
activate the effector caspases 3, 6 and 7, thereby eliciting apoptosis via the
extrinsic pathway or (ii) it can enter the intrinsic apoptotic pathway via interaction
with the Bcl-2 protein family. In this instance, caspase 8 will cleave the inactive
pro-apoptotic BH3-only protein “Bid” into its truncated and active form tBid. The
tBid then activates the Bcl-2 proteins Bax and Bak at the OMM. Bak and Bax
then undergo conformational changes as well as oligomerization thereby yielding
the formation of permeation pores on the OMM. Permeation pore formation elicits
the release of cytochrome c and Diablo/Smac from the mitochondrial IMS into the
cytosol. Once in the cytosol, cytochrome c and Diablo/Smac exert their proapoptotic effects in the same fashion as they do in the intrinsic apoptotic pathway
(27,36).
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Figure 1.4. The mixed pathway of apoptosis. Extracellular stimuli lead to
the formation of DISC and the subsequent activation of caspases 8 and 10.
Activated caspase 8 and 10 can cleave effector caspases to elicit cell death
via the extrinsic pathway or can enter the intrinsic pathway by interacting with
BCL-2 proteins. Caspase 8 converts Bid into tBid, which then interacts with
Bax/Bak inducing their oligomerization and formation of permeation pores on
the OMM, which facilitates the transport of apoptogenic proteins such as
cytochrome c and Diablo/Smac out of the mitochondria into the cytosol.

10

1.5 Capases
The caspases and the Bcl-2 protein family are primary regulators of Apoptosis.
The caspases are a group of cysteine proteases, which cleave proteins at sites
that are proximal to aspartic acid residues(37). Caspase activation is typically
considered the molecular hallmark of apoptosis(38). Caspases exist in their
inactive forms (pro caspase), and become activated during apoptosis by proapoptotic proteins(39).

While 12 caspases have been identified to date, not all play a role in the
regulation of apoptosis. For instance, caspase 1 is instrumental in the regulation
of biological processes that are unrelated to cell death including red blood cell
and skeletal muscle myoblast maturation. In contrast, caspase 14 is critical in
skin cell development(40).

There are two classes of caspases involved in apoptosis namely the initiator
(apical) and the effector (executioner) caspases. The initiator caspases include
caspases 2, 8, 9 and 10 and are activated in response to upstream apoptotic
stimuli. The initiator caspases cleave and process the effector caspases 3, 6 and
7. Upon activation, the effector caspases trigger cell death by degrading critical
intracellular structural proteins.
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1.6 The Bcl-2 proteins
The Bcl-2 family of proteins is a major regulator of the intrinsic pathway of
apoptosis. Their names derived from B-cell lymphoma/leukemia 2, and are the
second member of a collection of proteins initially discovered during
chromosomal translocations involving chromosomes 14 and 18 in human
follicular lymphomas (41). There are approximately 20 different members of the
Bcl-2 protein family. Bcl-2 protein family members all share one to four
homologous Bcl-2 homology (BH) domains that are important for homo and
hetero-dimeric interactions among different family members. Bcl-2 proteins are
either pro-apoptotic or anti-apoptotic (2,3,14) depending on the amount of BH
domains and their ability to regulate apoptosis(42).

Pro-apoptotic Bcl-2 proteins are important for the initiation and stimulation of the
intrinsic apoptotic pathway. These proteins are divided into two structurally and
functionally distinct categories: multi-domain and BH3-only Bcl-2 proteins(43).
Multi-domain pro-apoptotic Bcl-2 proteins Bak, Bax and Bok share three BH
domains (BH1-BH3). They are responsible for the formation of permeation
channels on the OMM that disturbs mitochondrial membrane integrity during
apoptosis. This facilitates the release of apoptogenic proteins from the
mitochondria into the cytosol (44). Bak and Bax are ubiquitously expressed in all
tissues while Bok is present only in reproductive cells (44). Bax and Bak are
localized in different subcellular compartments of healthy cells. In the presence of
death stimuli Bax undergoes conformational changes at both the amino- and
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carboxyl- termini eliciting its translocation from the cytosol to the OMM and the
eventual formation of large oligomeric complexes. Bak is localized solely in the
mitochondria and upon apoptotic stimuli, will undergo conformational changes
elicit the formation of oligomeric complexes (45,46). The oligomeric form of Bax
and Bak form permeation pores on the OMM (47). These permeation channels
mediate the release of pro-apoptotic proteins cytochrome c and Smac/Diablo
from the IMS of the mitochondria to the cytosol where they exert their effects.

1.7 Other cell death modalities - Autophagy and Necrosis
Autophagy is a tightly regulated, ordered cell death process. It is self-degradative
and essential for the maintenance of the balance of sources of energy at critical
stages of development as well as in response to nutrient deprivation(48).
Autophagy is also responsible for the removal of damaged organelles, misfolded
and aggregated proteins(49) and the elimination of intracellular pathogens(50).
The deregulation of autophagy has been implicated in non-apoptotic cell death.
Autophagy can be selective or non-selective in the removal of specific
organelles, ribosomes and protein aggregates(51). Furthermore, autophagy
promotes cellular senescence and cell surface antigen presentation. It protects
against genomic instability and is critical in the prevention of necrosis(50). Thus,
autophagy has a key role in the prevention of diseases including cancer,
neurodegeneration, liver diseases, autoimmune diseases, cardiomyopathy and
infections. Increased endocytosis, vacuolation, membrane blebbing and nuclear
condensation are all characteristic morphological hallmarks of autophagy. This
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type of cell death is categorized as a defensive reaction that can elicit cell death
or cell survival(50).

Another modality of cell death is necrosis. Necrosis is the irreversible loss of
plasma membrane integrity(52). It is a form of cell injury that results in the
premature death of cells in living tissue by autolysis. This type of cell death lacks
the features of apoptosis and autophagy, and typically is considered uncontrolled
(52,53). Necrosis is typically connected to immoderate cell loss in human
pathologies and can lead to local inflammation (54-56), thought to occur through
the liberation of factors from dead cells that alert the innate immune system
(53,54,57). Necrosis is signaled by irreversible cytoplasmic alterations
(condensation, fragmentation and loss of structure) and nuclear changes
(pyknosis, karyolysis and karyorhexis) (52,53). Infection, toxins and trauma can
result in the unregulated digestion of cell components leading to necrosis.

1.8 N-(3-oxododecanoyl)-homoserine lactone (C12)
The gram-negative opportunistic bacterium Pseudomonas aeruginosa produces
N-(3-oxododecanoyl)-homoserine lactone (C12) as a quorum-sensing molecule
used to facilitate bacteria-bacteria communication (7). Quorum sensing is a
bacterial communication system that releases and detects small diffusible
autoinducers (8,58). This system is responsible for the regulation of bacterial
gene expression in response to changes in cell population density(58). Gram
positive and gram-negative bacteria employ quorum-sensing communication to
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regulate variety of physiological functions including: symbiosis, antibiotic
production, conjugation, motility and biofilm formation(58). Mounting data has
shown that C12 is involved in the regulation of bacterial virulence genes and also
interacts with eukaryotic cells (59,60). As a small, lipid-soluble and diffusible
molecule, C12 readily enters cells of multiple tissues in the lungs of cystic fibrosis
patients including fibroblasts, epithelial cells, leukocytes, and endothelial cells
(9). Additionally C12 alters many aspects of eukaryotic cell physiology including
the inhibition of the secretion of proinflammatory cytokines (61-64), activation of
p53, and inhibition of events commonly associated with cell death (65-68). C12
has been shown to induce apoptosis in multiple types of cancer cells (66,69-71).
C12 induces apoptosis by inhibiting phosphatidylinositide3-kinases, arresting
Akt/PKB pathway and attenuating STAT3 activity in breast carcinoma cells
(8,66). In pancreatic carcinoma cells, C12 induces apoptotic signaling and
inhibits cell migration (8,70). In colorectal cancer cells, C12 reduces the
expression of thymidylate synthase while enhancing the activity of otherwise
conventional chemotherapeutic agents including 5-fluorouracil (5-FU) (69).
Comparative SAR analysis has indicated that long acyl side chains with a 3-oxo
substitution are essential for C12’s anti-cancer effect (69). However, the exact
signaling pathway(s) leading to C12-triggered cell death remains unclear. Our
preliminary studies indicate that C12-triggered tumor cell apoptosis occurs by
selectively activating the mitochondria-specific intrinsic pathway through a novel
mechanism that is independent of activities of both anti- and pro-apoptotic Bcl-2
proteins in human tumor cells. We also find that C12 induces apoptosis
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preferentially in oncogenically transformed but not in non-transformed human
bronchial epithelial cells. Importantly, we discovered that C12 cytotoxicity is
mediated through the lactonase activity of paraoxonase 2 (PON2).

1.9 Paraoxonase 2 (PON2)
PON2 is a ubiquitously expressed mammalian protein with anti-oxidant
properties and lactonase/arylesterase activities (72,73), and it rapidly hydrolyzes
C12 to C12-acid, which becomes trapped and accumulates within human
bronchial epithelial cells, particularly in mitochondria (74-77). PON2 is
upregulated in many types of cancer, including lung cancer, enabling cancer cells
to resist conventional therapeutic drugs (78,79). PON2 expression also prevents
oxidation and inflammation, but the detailed mechanisms remain unclear. This
membrane-bound protein’s expression is markedly elevated in several human
non-small cell lung carcinoma (NSCLC) cell lines. Mutations in the Pon2 gene
may be associated with vascular disease and a number of phenotypes related to
diabetes.

An important anti-tumor approach is the identification of small molecules that
preferentially trigger tumor cell apoptosis regardless of the Bcl-2 protein profile in
tumor (4,5). The quorum-sensing molecule C12 preferentially induces
transformed cell apoptosis in vitro and inhibits transplanted tumor growth in vivo
independent of both anti- and pro-apoptotic Bcl-2 proteins. The apoptosis
cascade induced by C12 in tumor cells is unique, evident by its rapid pro-
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apoptotic effects, such as depolarization of mitochondrial membrane potential
within minutes, release of cytochrome c into the cytosol within one hour and
detection of maximal activation of caspases within four hours. This distinctive
pro-apoptotic feature of C12 has not been observed in any other apoptosis
paradigms, which might be attributed to the ability of C12 or its metabolite(s) to
directly permeabilize mitochondria (within minutes) without involving Bcl-2
proteins. Furthermore, lung tumor cells are resistant to conventional therapeutic
drugs partially due to overexpression of paraoxonase 2 (PON2), a protein with
anti-oxidant properties and lactonase/ arylesterase activities (80,81).
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CHAPTER 2: MATERIALS AND METHODS
2.1. Reagents
N-(3-oxododecanoyl)-homoserine lactone (C12) was purchased from Sigma (St.
Louis, MO). Propidium iodide (PI) was obtained from Invitrogen (Carlsbad, CA).
Unless otherwise stated, all reagents were dissolved in dimethyl sulfoxide
(DMSO). Dulbecco’s Modified Eagle’s Medium (DMEM), penicillin/streptomycin,
trypsin, and L-glutamine were obtained from Mediatech (Manassas, VA), and
fetal bovine serum (FBS) was purchased from Gemini (Broderick, CA). CaspaseGlo assay 3/7 kit was purchased from Promega (Madison, WI). Antibodies (Abs)
used for western blot analysis were anti-β-actin mAb (Sigma), anti-caspase-3
pAb (Cell signaling; Danvers, MA), anti-caspase-7 pAb (Cell signaling), anticaspase-8 pAb (Cell signaling), anti-caspase-9 pAb (Cell signaling), anti-Bax pAb
(Santa Cruz; Dallas, TX), anti-Bak pAb (Millipore; Billerica, MA), anti-Bcl-2 mAb
(Santa Cruz), anti-human PON2 (Abcam; Cambridge, MA), anti-murinePON2
(Antibodies-on-line; Atlanta, GA), peroxidase-conjugated goat anti-rabbit IgG
(Thermo; Waltham, MA) and peroxidase-conjugated goat anti-mouse IgG
(Thermo).

2.2. Cell lines and cell culture
Immortalized mouse embryonic fibroblasts (MEFs) deficient in the expression of
caspase-8 and their wild-type counterparts were provided by Professor David
18

Vaux (Walter and Eliza Hall Institute of Medical Research, Parkville, VIC
Australia). MEFs lacking caspase-9 and their wild-type counterparts were
obtained from Professor Jerry Adams (Walter and Eliza Hall Institute of Medical
Research). MEFs lacking caspase-3, caspase-7, caspase-3 and caspase-7, or
their wild-type counterparts were obtained from Professor Richard Flavell (Yale
University). HCT116 cells expressing different levels of Bak and Bax were
obtained from Dr. Richard Youle (National Institutes of Health). NSCLC cell line
A549 and NCI-H1299 cells were obtained from ATCC. A549 cells
overexpressing Bcl-2 were produced by retroviral infection as described
previously (8). To generate NCI-H1299 or A549 cells with reduced PON2
expression or vector control, we infected cells using respective lentiviral
supernatants with 10 µg/ml polybrene. Stable cell lines were obtained by
culturing cells in the medium containing1.5 g/ml puromycin. NHBE cells were
purchased from Lonza (Walkersville, MD). hT/LT/Ras HBE cells were obtained
from Professor Barrett Rollins (Harvard Medical School). Lewis Lung Carcinoma
cells, NCI-H1299 and A549 cells were cultured as described previously (8).
NHBE and hT/LT/Ras cells were grown in BEGM supplemented with
SingleQuots (LONZA). HCT116 cells were grown as described previously (8).
Cells were all cultured in a 5% CO2 humidified incubator at 37oC.
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2.3. Cell viability/Death assays
The indicated MEF cell lines were plated in a 48-well tissue culture plate with
20,000 cells in each well and cultured for 24 hours. Following the treatment with
different concentrations of C12, cells were harvested in the presence of 1.0 µg/ml
propidium iodide (PI). Cell viability was measured by PI exclusion using flow
cytometry (FACSCalibur, Becton Dickinson) (FACScalibur, Beckon Dickinson;
San Jose, CA). The percentage of cell death is determined as 100 minus the cell
viability measurement.

2.4. Caspase-3/7 activity
Caspase-3/7 activities were measured using a Caspase-Glo assay kit (Promega,
Madison, WI, USA) (82). In this assay, the proluminescent substrate containing
the amino acid sequence Asp-Glu-Val-Asp (DEVD) is cleaved by activated
caspase-3/7, resulting in the release of a luciferase substrate (aminoluciferin)
and the production of luminescent signal. Briefly, 24 hours before the treatment,
cells were plated in white-walled 96-well plates. At the indicated time points
following treatment with various molecules, cells were mixed with CellTiter-Glo
reagent and the luminescence was quantified by a Gemini EM microplate
spectrofluorometer (Molecular Devices; Sunnyvale, CA) according to the
manufacturer’s protocols. Data were presented as relative fluorescence units
(RFUs).
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2.5. Western blot analysis
Equal amounts of proteins (30 µg) were separated on a 4-12% Bis-Tris gel (BioRad; Hercules, CA) and transferred onto PVDF membrane (Millipore; Billerica,
MA). The membrane was incubated with appropriate primary or secondary
antibodies either overnight at 4oC or at room temperature for 3 hours in 1X
phosphate-buffered saline (PBS) containing 5% (w/v) nonfat dry milk (Bio-Rad)
and 0.2% (v/v) Tween 20. Protein levels were detected using the enhanced
chemiluminescent detection system (Pierce; Rockford, IL) as described
previously(83).

2.6. Measuring Δmito using imaging microscopy of JC1
For imaging experiments to measure mitochondrial membrane potential (Δmito),
cells were incubated with growth media containing the Δmito probe JC1 (10 μM)
for 10 minutes at room temperature, and then washed three times with Ringer’s
solution to remove the extra dye. JC1-loaded cells were placed onto a chamber
on the stage of a Nikon Diaphot inverted microscope. Cells were maintained at
room temperature during the experiment. Treatments were made by diluting
stock solutions into Ringer’s solution at the concentrations stated in the text.
Fluorescence imaging measurements of Δmito were performed using equipment
and methods that have been reported previously (7,14). Briefly, a Nikon Diaphot
inverted microscope with a Fluor 20 X objective (0.75 numerical apertures) was
used. A charge coupled device camera collected JC-1 emission images (green:
510–540 nm; red: 580–620 nm) during excitation at 490 +/- 5 nm using filter
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wheels (Lambda-10, Sutter Instruments, Novato, CA). Axon Imaging Workbench
5.1 (Axon Instruments, Foster City, CA) controlled filters and collection of data.
Images were corrected for background (region without cells). Quantitative data
are reported as JC1 fluorescence ratios normalized to minimal JC1 ratios
obtained at the start of the experiment and maximal JC1 ratios obtained after
treatment with 5 μM FCCP.

2.7. Detection of the release of cytochrome c from mitochondria
Mitochondria were purified from MEF cells as described previously (84). Isolated
mitochondria were resuspended in buffer containing 12 mM HEPES (pH 7.5), 1.7
mM Tris-HCl (pH 7.5), 100 mM KCl, 140 mM mannitol, 23 mM sucrose, 2 mM
KH2PO4, 1 mM MgCl2, 0.67 mM EGTA, and 0.6 mM EDTA supplemented with
protease inhibitors (Complete; Roche Diagnostics, Indianapolis, IN). After one
hour incubation with C12 at 30°C, mitochondrial vesicles were centrifuged at
10,000×g for 10 min, and vesicles were dissolved in 1×SDS-PAGE loading buffer.
Proteins in the vesicle fractions were detected by Western blotting.

2.8. Electrophysiological experiments
Solvent free planar phospholipid membranes were formed across a 0.1 mm hole
in a Saran partition by the monolayer method (60,61). The monolayers were
formed by layering the lipid solution (0.5% (w/v) diphytanoylphosphatidylcholine,
0.5% (w/v) asolectin (polar extract of soybean phospholipids), and 0.05% (w/v)
cholesterol in hexane) on the surface of the aqueous solutions (1.0 M KCl, 1 mM
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MgCl2, and 5 mM PIPES, pH 6.9) on either side of the partition. The
phospholipids were purchased from Avanti Polar Lipids. Calomel electrodes
were used to interface with the aqueous phase. The membrane voltage was
clamped using a high-quality operational amplifier in the inverted mode and the
current recorded using Clampex 10.3 software. Data was low-pass filtered at
500 Hz when recorded. Typically 20-50μL of 0.7 mg/ml C12 (dissolved in 95%
isopropanol, 5% DMSO) was dispersed with rapid stirring into a 5mL aqueous
solution on one side of the membrane, labeled “cis” side. All voltages referred to
the cis side, the trans being held at virtual ground by the amplifier. Vehicle
controls produced no conductance.

2.9. Immunofluorescence microscopy
MEF cells plated onto cover glasses 24 hours earlier were rinsed with Ringer’s
solution and incubated for 4 hours with either vehicle (DMSO) or 50 µM C12 in
Ringer’s solution. The immunofluorescence staining of cytochrome c and tom20
were carried out as described previously (Zhao et al., JBC, 2015). Images were
captured using a Nikon Eclipse Ti confocal microscope (Nikon; Melville, NY)
equipped with a PlanApo 60x, 1.42 NA oil immersion objective. To minimize
variability for quantitative assessment, the same microscope settings were used
across vehicle control and C12-treated samples for three individual experiments.
Four to nine fields of view were captured to acquire a sample size of at least 100
cells for each individual experiment. Quantification of cytochrome c and tom20
percentage of overlap was performed using ImageJ (NIH). For each image,
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Maximum Intensity Projections (MIPs) were first created for both the cytochrome
c and tom20 channels. Using tom20 as a guide, regions of interest (ROIs) were
drawn around the cytoplasm of the cells, and these ROIs were copied onto the
cytochrome c and tom20 MIPs. The percent area of pixels above a set threshold
was calculated for every ROI (cell) for both cytochrome c and tom20. The
thresholds, although set differently for cytochrome c and tom20, were kept the
same for every image across control and C12-treated samples to reduce bias.
Percent overlap between cytochrome c and tom20 was calculated as (percent
area cytochrome c/percent area tom20)*100.

For immunofluorescence staining of tumor sections, tumor sections (5 μm) were
treated with antigen retrieval procedure by boiling in 10% Triton x-100, then
slowly cooled down at room temperature. After incubating with the blocking buffer
(1× PBS, 0.2% Triton X-100, 5% goat serum), the slides were incubated with
antibodies against activated caspase-3 (Cell signaling) overnight at 4oC.
Following three 10-minute washes, slides were incubated with goat anti-rabbit
IgG (Alexafluor-568, Invitrogen) for 1 hour. The fluorescence was visualized by
confocal microscopy using a 40x CFI Plan Fluor objective (NA 0.6)

2.10. Cell cycle analysis and cell proliferation assay
For cell cycle analysis, 5×105 cells were sedimented (300 x g for 5 minutes) and
washed twice with 500 µl 1 x PBS. Cells were then fixed with 1 ml 70% ethanol
in 1 x PBS at 4oC overnight. After centrifugation, cells were washed twice with 1
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x PBS and resuspended in 500 µl 1 x PBS. 50 U RNase A (Qiagen, Valencia,
CA) were added to samples and incubated at 37oC for 1 hour. Five µg propidium
iodide was added to samples which were incubated for 30 minutes at 37 oC
before flow cytometric analysis. To evaluate cell proliferation, 1.5×104 cells were
plated in wells of a 12-well plate and the total cell number was determined by
using a hemocytometer.

2.11. In vivo animal studies
For transplanted tumors in C57BL/6 mice, eight-week old C57BL/6 female mice
(Jackson Laboratories; Bar Harbor, ME) were inoculated subcutaneously (s.c.)
with 1×106 Lewis Lung Carcinoma cells on the right flank. Tumors were
measured daily with dull edged Vernier calipers (V = L×W 2/2). After tumor size
reached around 100 mm3, animals with size-matched tumors were divided into
control group and C12 group. DMSO or C12 was administered intraperitoneally
each day. At the end of the experiments, tumors were excised for apoptosis
evaluation. TUNEL labeling was carried out by the Pathology Research Services
Laboratory at University of Washington. The slides were scanned by a
ScanScope CS digital slide scanner (Aperio; Vista, CA).

2.12. Statistical analysis
All experiments were performed in triplicate at least three times. Results are
presented as mean ± standard deviation. Statistical analysis was performed
using Student’s two tail t-test. A p value < 0.05 was considered significant.
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CHAPTER 3: RESULTS
3.1 Caspase-3 and caspase-7 were required for C12-induced cell death.
In multicellular organisms, cell death is a highly heterogeneous process in which
several distinct, in some cases partially overlapping, cell signaling cascades can
be activated (1). Although C12’s ability to trigger the events commonly linked to
apoptosis has been reported (References 56, 60, 63, 65, 66), it is unclear
whether other cell death signaling is involved. To thoroughly explore C12induced cell death signaling, we first investigate whether caspase-3 and
caspase-7 are essential to mediate cytotoxic effects of C12 Cytotoxicity of C12
was examined in MEF cells lacking only caspase-3 (caspase-3-KO), only
caspase-7 (caspase-7-KO), or both of them as well as their wild-type (WT)
counterparts (Figure 3.1A). C12 induced significant cell death in WT, caspase-3KO and caspase-7-KO MEF cells, whereas caspase-3/7-DKO MEF cells were
completely resistant to C12 exposure (Figure 3.1B). Moreover, less cell death
was observed in caspase-3-KO or caspase-7-KO MEFs than their wild-type
counterparts, indicating that both caspase-3 and caspase-7 are involved in
apoptosis signaling initiated by C12, although caspase-3 appears to play a more
prominent role. The essential role of caspase-3 and caspase-7 indicates that cell
death induced by C12 is largely attributed to apoptosis.
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Figure 3.1. Caspase-3 and caspase-7 were required for C12-induced cell
death (A) Caspase-3 and caspase-7 expression in MEF cells was examined
via western blot analysis. (B) The indicated MEFs were treated with various
concentrations of C12 for 48 hours and cell viability was measured by
propidium iodide exclusion using flow cytometry. Cell death data are shown
as mean ± standard deviations of 3 independent experiments. Asterisks
indicate P < 0.05 (*); Student's unpaired t test.
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3.2. Caspase-3 and caspase-7 were not required for mitochondrial
depolarization.
Mitochondrial outer membrane permeabilization (MOMP) has been recognized to
be a “no-return” step in both intrinsic and extrinsic apoptotic pathways (1). To
further explore C12-initiated apoptotic signaling, we first studied the involvement
of caspase-3 and caspase-7 in the key event of MOMP: depolarization of
mitochondrial membrane potential (∆mito). Depolarization of Δmito was
evaluated by determining the changes in fluorescence with the voltagedependent dye JC1 being released from mitochondria into the cytosol and
nucleus. Within minutes of C12 exposure, mitochondria in MEFs were largely
depolarized to a degree close to the complete depolarization of Δmito induced by
the ionophore FCCP (Figure 3.2A). Importantly, depolarization of Δmito occurred
at similar levels in WT and caspase-3/7-DKO MEF cells upon C12 exposure,
indicating that MOMP induced by C12 occurs upstream of “effector” caspase
activation (Figure 3.2B).
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Figure 3.2. Caspase-3 and caspase-7 were not required for
mitochondrial depolarization. (A) C12’s effect on mitochondrial potential is
independent of caspase-3 and caspase-7. MEFs were loaded with the
mitochondrial potential dye JC-1, and its fluorescence was measured using
imaging microscopy during the treatment with 50 µM C12 and 10 µM FCCP.
Typical results are shown. (B) C12 caused equivalent depolarization of
mitochondrial potential in both WT and caspase 3/7-DKO MEF cells. Means
+/- standard deviations for 3 experiments are shown. Responses of WT and
caspase-3/7- DKO MEFs are not significantly different (p>0.05). Student’s
unpaired t test.
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3.3. C12-induced mitochondrial outer membrane permeabilization occurs
upstream of caspase-3/7 activation.
To validate these observations, we studied the involvement of caspase-3 and
caspase-7 in another key event of MOMP, cytochrome c release from
mitochondria into the cytosol. We performed immunofluorescent studies to
evaluate C12-evoked redistribution of cytochrome c to the cytosol/nuclei. Upon
C12 treatment, intracellular distribution of cytochrome c was diffuse in the cytosol
and nuclei in both WT and caspase-3/7-DKO MEFs, whereas Tom20 maintained
its characteristic mitochondrial distribution, demonstrating that mitochondria in
WT and caspase-3/7-DKO MEFs were permeabilized with cytochrome c released
into the cytosol and diffused into the nuclei (Figure 3.3A). The redistribution of
cytochrome c was evaluated by calculating the percentage of overlapping
between cytochrome c and Tom20, and the results indicate that C12 caused
equivalent cytochrome c release in WT and caspase-3/7-DKO MEFs (Figure
3.3B). Overall, our results provide more evidence that C12 triggers MOMP
independent of caspase-3 and caspase-7 activation.
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Figure 3.3 C12-induced mitochondrial outer membrane permeabilization
occurs upstream of caspase-3/7 activation. (A) Representative confocal images
of MEF cells treated with either DMSO (control) or 50 µM C12 for 4 hours. The
mitochondrial marker Tom20 is shown in red, cytochrome c is in green and DAPI in
blue. Following the treatment with C12, staining of cytochrome c became diffuse
and lost its co-localization with Tom20. (B) Cytochrome c is released from both WT
and caspase-3/7-DKO MEFs to the similar degree upon C12 exposure. Threshold
intensity of cytochrome c is compared to that of Tom20 for over 100 cells across
control and C12 treated samples. Data represent means +/- standard deviations for
three independent experiments. Student’s unpaired t test.
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3.4. Caspase-8 and caspase-9 plays distinct roles in C12-induced apoptosis.
While it has been shown that C12 induces an apoptotic modality of cell death, the
exact signaling pathway remains unclear. It is well accepted that caspase-8
activity is characteristic of the extrinsic apoptotic pathway while caspase-9
activity is hallmark of the intrinsic apoptotic pathway. To elucidate which
apoptotic pathway is triggered in C12 induced cell death, we studied two pairs of
MEF cells deficient in either caspase-8 or caspase-9 and their wild-type
counterparts. Upon treatment with C12, similar levels of cell death were detected
in both WT and caspase-8-KO MEF cells (Figure 3.4B). In agreement with cell
death data, caspase-3/7 was activated regardless of caspase-8 expression,
indicating that caspase-8-mediated extrinsic pathway is not involved in C12induced apoptosis in MEFs. In contrast, MEFs deficient in caspase-9 expression
were completely resistant to C12 treatment (Figure 3.4E). Furthermore, C12
failed to evoke any significant activation of cspase3/7 (Figure 3.4F). Overall,
these data suggest that C12 induces apoptotic signaling largely through
activating the mitochondria-dependent intrinsic apoptotic pathway in MEFs.
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Figure 3.4. Caspase-8 and caspase-9 plays distinct roles in C12-induced
apoptosis. (A) Caspase-8 expression in MEF cells was examined by western
blot. (B) Caspase-8 activation is not involved in C12-induced cell death. The
cytotoxicity of C12 on MEFs was assessed 24 hours following the exposure by
a propidium iodide DNA dye exclusion approach. (C) Caspase-3/7 activities
were measured 24 hours after C12 treatment. (D) Caspase-9 expression in
MEF cells was determined by western blot. (E) Wild-type and caspase-9-KO
MEFs were treated with C12, and cell viability was measured 48 hours later.
(F) Upon C12 treatment for 24 hours, caspase-3/7 activities were determined.
All data are shown as means ± standard deviations of 3 independent
experiments. Asterisks indicate P < 0.05 (*); Student's unpaired t test. ns, no
significance.
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3.5. C12-induced mitochondrial potential decrease is independent of caspase-8
and caspase-9.
To further explore the roles of the “initiator” caspases in MOMP mediated by
C12, depolarization of Δmito was examined in caspase-8-KO or caspase-9-KO
MEF cells or their WT counterparts respectively. Consistent with its effects on
cell viability and caspase-3/7 activation (Figures 3.4B-C), deficiency in
caspase-8 expression did not affect quick depolarization of Δmito (Figures
3.5A-B). Similarly, C12 caused the same levels of Δmito depolarization in WT
and caspase-9-KO MEF cells (Figures 3.5C-D), indicating that the “initiator”
caspases are not involved in C12- induced MOMP.
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Figure 3.5 C12-induced mitochondrial potential decrease is independent
of caspase-8 and caspase-9. (A) The mitochondrial potential of the WT and
caspase-8-KO MEF cells loaded with JC-1 was determined by fluorescent
microscopy upon the treatment with 50 µM C12 and 10 µM FCCP.
Representative results were shown. (B) C12 caused equivalent mitochondrial
depolarization in WT and caspase-8-KO MEF cells. (C) Mitochondria in WT
and caspase-9-KO MEF cells were depolarized to the similar degrees upon
the treatment of 50 µM C12 and 10 µM FCCP. (D) Summary of the data
shown in (I). All data are shown as means ± standard deviations of 3
independent experiments. Student's unpaired t test. ns, no significance.
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3.6. C12-induced caspase-9 activation occurs downstream of mitochondrial
membrane permeabilization.
We have demonstrated that caspase-9 activation is involved in C12-induced
apoptosis. To further elucidate the involvement of caspase-9 activation, we
examined cytochrome c redistribution from mitochondria to the cytosol/nuclei
upon C12 exposure using immunofluorescence staining. While C12 evoked the
release of cytochrome c from mitochondria to the cytosol/nuclei regardless of
caspase-9 expression, Tom20 displayed typical punctate and perinuclear
mitochondrial distribution following C12 treatment (Figure 3.6A). Moreover, C12
caused similar level of cytochrome c release from mitochondria in WT and
caspase-9-KO MEF cells (Figure 3.6B). Taken together, these data indicate that
C12 causes acute MOMP independent of any “initiator” caspase, suggesting that
the effects of C12 on MOMP might be attributed to its direct action of on
mitochondria.
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Figure 3.6. C12-induced caspase-9 activation occurs downstream of
mitochondrial membrane permeabilization. (A) Representative confocal images of
MEF cells treated with either DMSO (control) or 50 µM C12 for 4 hours. The
mitochondrial marker Tom20 is shown in red, cytochrome c in green, and DAPI in
blue. Following the treatment with C12, staining of cytochrome c became diffuse and
lost its co-localization with Tom20. (B) Cytochrome c is released from both WT and
caspase-3/7-DKO MEFs to the similar degree upon C12 exposure. Threshold
intensity of cytochrome c is compared to that of Tom20 for over 100 cells across
control and C12-treated samples. Data represent means +/- standard deviations of
three independent experiments. Student's unpaired t test.
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3.7. C12 directly induces mitochondrial outer membrane permeabilization in vitro.
Since C12 depolarized Δmito within minutes independent of both “initiator”
caspases and “effector” caspases (Figures 3.2 and 3.5), we reasoned that C12
could possess activities directly permeabilize mitochondria. To this purpose, we
examined the effects of C12 on mitochondrial outer membrane integrity in vitro.
Mitochondria isolated from WT MEF cells were incubated various concentrations
of C12. We assessed the amount of cytochrome c released from the
mitochondria using western blot analysis (Figure 7A). In a manner dependent of
C12 doses, less cytochrome c was detected in mitochondrial fractions with
concurrent increase of cytochrome c in released fractions, indicating that C12 is
able to permeabilize mitochondria directly in vitro.
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Figure 3.7. C12 directly induces mitochondrial outer membrane
permeabilization in vitro. (A) Mitochondria was isolated from wild-type MEFs
and incubated with C12. The cytochrome c release from mitochondria induced
by C12 was determined by western blot. (B) The intensities of cytochrome c in
mitochondrial fractions and released fractions shown in (A) were quantified
using the software ImageJ (NIH). Cytochrome c release is represented as a
percentage of the sum of the protein intensity mitochondrial fractions and
released fractions. Mean ± standard deviation for three independent
experiments are shown. Asterisks indicate P values of ˂ 0.05 (*) or ˂ 0.01 (**)
by Student’s unpaired t test.
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3.8. C12 forms channels with large conductance in phospholipid membranes in
vitro.
The amphipathic lipid ceramide forms large stable permeation channels in the
mitochondrial outer membrane capable of releasing proteins (85,86). As C12
directly induce MOMP in vitro (Figure 3.7), we postulated that amphipathic C12
might possess similar activities. Thus, we studied whether C12 is capable of
forming large conductance pathways in phospholipid membranes lacking any
proteins. Following the addition of C12 to planar phospholipid membranes, the
conductance increased slowly reaching steady levels but with frequent
increases and decreases in conductance (Figure 8A). The formation of the
conductance consisted of discrete conductance increments that are
characteristic of channels with various magnitudes. Upon the addition of LaCl3,
conductance formed by C12 was rapidly lost, suggesting that it was not caused
by defects in the membrane (Figure 3.8A). This was reversed by chelation of
the lanthanide with EDTA. Furthermore, the discrete conductance changes
showed a log-normal distribution, which is typical of substances of varying size
(Figure 3.8B). However, the distribution of conductance does not seem to be a
continuum but rather shows indications of preferential conductance that is
multiples of 16 nS. The results are consistent with C12 forming large channels
of variable size that grow and shrink by incorporating or losing assemblies of
C12 lipids, suggesting that C12 might directly function on mitochondria to
induce MOMP (Figure 3.8D).
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Figure 3.8. C12 forms channels with large conductance in phospholipid
membranes in vitro.
(A) Formation and reversible disassembly of C12 channel(s) in a planar
phospholipid membrane. At the indicated time points, C12, LaCl3, or EDTA was
added to the aqueous phase on one side (cis side) of the membrane. (B)
Distribution of C12-induced conductance changes in phospholipid membranes.
Sudden changes in conductance were measured and grouped into bins in log
scale as appropriate for the apparent log-normal relationship of the data. The
data are pooled from 7 separate experiments. (C) Distribution of C12-induced
conductance measured on occasions of sudden conductance changes. Four
nanoSiemen bins were used for the histogram. These are pooled data from 7
separate experiments. (D)The proposed model of C12 or C12 metabolite(s)
functioning as a mitolytic molecule to directly cause MOMP.
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3.9. C12 inhibits LLC tumor growth and induces tumor cell apoptosis in vivo in
a dose-dependent fashion.
The cytotoxic effects of C12 on tumor cells have been reported previously
(66,69,74,80), but whether they are selective for transformed cells was
unknown. To investigate whether oncogenic transformation influences the
cytotoxicity of C12, we studied normal human bronchia/tracheal epithelial
(NHBE) and corresponding HBE immortalized and transformed successively by
telomerase, SV40 large T antigen and activated Ras (H-ras V12). This is a
well-established epithelial cell malignant transformation system related to
human lung cancer (87). Upon C12 treatment, we observed higher levels of
cell death and caspases-3/7 activation in transformed HBE cells than in their
untransformed counterparts. This indicates that C12 induces apoptosis
preferentially in transformed cells (Figure 3.9A-B). To investigate the relevance
of C12 cytotoxicity on transformed cells to tumor growth in animals, we
examined the effects of C12 on the growth of established Lewis Lung
Carcinoma (LLC) tumors. We found that transplanted tumors grew much more
slowly in C12-treated mice than in vehicle-treated mice, revealing a dose
dependent anti-tumor activity of C12 as a single agent (Figure 3.9C). By
evaluating caspase3/7 activation and TUNEL labeling, we found that apoptosis
is involved in the inhibitory activity of C12 in vivo (Figure 3.9D-F).
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Figure 3.9. C12 inhibits LLC tumor growth and induces tumor cell
apoptosis in vivo in a dose-dependent fashion. (A-B) Cytotoxicity of C12 is
affected by oncogenic transformation. C12’s effects on HBE cell viability (A)
and caspase-3/7 activation (B) were examined. All data shown are mean ±
standard deviation of 3 independent experiments. Asterisk indicates P < 0.05
(*) or P< 0.01 (**) by student's unpaired t test. (C) The inhibitory effects of C12
on the growth of LLC tumors were studied. Tumors were measured daily and
tumor tissues were removed at the end of treatments. Data are shown as mean
± standard deviation of tumor volumes of 7 animals in either vehicle control or
C12-treated group. Asterisk indicates P < 0.05 (*) by student’s unpaired t test.
(D) Apoptotic cells in tumor sections were detected by immunofluorescence
staining of activated caspase-3. Representative images of tumor sections are
shown. Scale bar, 50 µm. (E) TUNEL staining of apoptotic cells in control or
C12-treated tumor sections. Representative images are shown. Scale bar, 60
µm. (F) The percentage of apoptotic cells shown in (E) was quantified using
ImageJ software. Data are mean ± standard deviation of three independent
tumor sections. Asterisk indicates P < 0.05 (*) or P< 0.01 (**) by student’s
unpaired t test.
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3.10. C12 induces tumor cell apoptosis independent of anti-apoptotic Bcl-2
proteins.
Anti-apoptotic Bcl-2 proteins are frequently overexpressed in human cancers
and associated with chemotherapeutic resistance and relapse(88). To
investigate the involvement of anti-apoptotic Bcl-2 proteins in C12-induced
human tumor cell apoptosis, Bcl-2 was stably overexpressed in A549 cells by
retroviral infection (Figure 3.10A). The anti-tumor drug actinomycin D caused
less cell death and less caspases-3/7 activation in Bcl-2-overexpressing cells
than in cells expressing the empty vector. In contrast, C12 induced similar
levels of cell death and caspase-3/7 activation in cells overexpressing Bcl-2
and the vector control cells (Figure 3.10B-C). We also investigated whether
C12’s effect on mitochondrial membrane potential is dependent of Bcl-2.
A549-vector and A549-Bcl-2-overexpressing cells were loaded with JC1, and
its fluorescence was measured using imaging microscopy (Figure 3.10D-E).
Within minutes of C12 exposure, mitochondria in A549-vector cells and A549Bcl-2 overexpressing cells were depolarized to the same degree, providing
more evidence that C12 evokes apoptosis independent of anti-apoptotic Bcl-2
proteins.
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Figure 3.10. C12 induces tumor apoptotic cell death independent of
anti-apoptotic Bcl-2 proteins. (A) Retrovirally overexpressed Bcl-2 in
A549 cells was examined by western blot. (B) Cell viability was measured
48 hours after C12 or actinomycin D (ActD) exposure. (C) Caspase-3/7
activities were determined following 2 hour exposure to C12 and 24 hour
exposure to actinomycin D. (D) C12’s effect on mitochondrial membrane
potential is independent of Bcl-2. A549-vector and A549-Bcl-2overexpressing cells were loaded with JC1, and its fluorescence was
measured using imaging microscopy during the treatment with 100 µM
C12 and 5 µM FCCP. Typical results from three independent experiments
are shown. (E) C12 caused equivalent depolarization of mitochondrial
potential in vector and Bcl-2-overexpressing A549 cells. All data are
shown as mean ± standard deviation of three independent experiments.
Asterisks indicate P < 0.05 (*); ns, no significant by student's unpaired t
test.
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3.11. C12-induced tumor cell apoptosis is independent of Bak and Bax.
Previous studies show that C12 induces apoptosis in MEFs independent of
Bak and Bax (9), two pro-apoptotic Bcl-2 members required for MOMP in
almost all apoptotic paradigms (3). To elucidate whether Bak and Bax are also
involved in C12-induced tumor cell apoptosis, human colon carcinoma HCT116
cell lines deficient in Bak alone (Bak-KO), Bax alone (Bax-KO), or both Bak
and Bax (Bak/Bax-DKO) were investigated (Figure 3.11A). We found that C12
caused equivalent cell death and caspase-3/7 activation in all the HCT116 cell
lines examined (Figure 3.11B-C). This indicates that deficiency of Bak or Bax in
HCT116 cells did not influence their responses to C12. Furthermore, deficiency
in Bak/Bax expression did not affect C12’s effect to depolarize Δmito (Figure
3.11D-E).
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Figure 3.11. C12-induced tumor cell apoptosis is independent of Bak and
Bax. (A) Bak and Bax expression in the indicated HCT116 cells was examined
by western blot. (B-C) C12 induced similar levels of cell death (B) and
caspase-3/7 activation (C) among WT, Bak-KO, Bax-KO and Bak/Bax-DKO
HCT116 cells after 24 hours treatment. (D) The mitochondrial potential of the
WT and Bak/Bax-DKO HCT116 cells loaded with JC1 was determined by
fluorescent microscopy upon the treatment with 50 µM C12 and 5 µM FCCP.
Representative results are shown. (E) Summary of the data shown in (D). All
data are presented as mean ± standard deviation of three different
experiments. ns, no significant.
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3.12. PON2 expression is enhanced in human lung tumor tissues
and oncogenically transformed HBE cells.
It has been shown that PON2 upregulation in some cancer cells, including lung
cancer cell lines, enables cancer cells to become resistant to conventional
therapeutic drugs (80). To determine whether PON2 expression is enhanced in
human lung cancer, we examined PON2 protein levels in tumor tissues of nonsmall cell lung carcinoma (NSCLC) patients by western blot. Among eleven
samples from patients, we found that PON2 was overexpressed in eight of lung
cancer tissues compared with corresponding adjacent normal tissues, whereas
its expression was slightly decreased in three of them (Figure 3.12A). As Rastransformed HBE displayed higher levels of apoptosis compared with their
untransformed counterparts upon C12 treatment (Figure 3.9A-B), PON2
expression was also increased in transformed HBE cells. These observations
provide more evidence that oncogenic transformation enhances PON2
expression (Figure 3.12C).
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Figure 3.12. PON2 expression is enhanced in human lung tumor tissues
and oncogenically transformed HBE cells. (A) Expression of PON2 in
NSCLC tissue specimens and corresponding adjacent normal tissues from 11
patients were evaluated by western blot. Samples 1-4, 6, 8, 9, 11 were from
adenocarcinoma patients, whereas samples 5, 7, 10 were from squamous cell
carcinoma patients. T, tumor; N, normal. (B) The intensities of bands in (A) were
quantified using ImageJ software (NIH). To normalize loading variation, the
relative levels of PON2 were calculated by dividing the PON2 value into the
corresponding value for actin. The data were shown as a ratio of PON2 levels in
a tumor tissue sample versus its corresponding normal tissue, and the value
bigger than 1 indicates that PON2 expression is increased in tumor tissues.
Differential expression of PON2 in tumor versus normal tissues is significant
with the value of “P” smaller than 0.01 as calculated by student’s paired t test.
(C) The expression of PON2 and PON3 in primary HBE cells and their
transformed counterparts was determined by western blot.
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3.13. PON2 is required in C12 cytotoxicity in human lung tumor cells.
Overexpression of PON2 promotes cytotoxicity of C12 in non-transformed MEF
and HEK293T cells (9), but the role of endogenous PON2 in C12-induced
apoptotic signaling is unclear. To further investigate the mechanism of C12triggered apoptosis, we investigated the prospective involvement of endogenous
PON2 in C12 cytotoxicity in tumor cells. We employed shRNA to stably reduce
PON2 expression in human NSCLC cell lines A549 and NCI-H1299. Treatment
with C12 elicited less cell death and caspase-3/7 activation in A549 and NCIH1299 cells lacking PON2 expression (Figure 3.13). Conversely, increased cell
death and caspase-3/7 activation observed in PON2-deficient cells in response
to the conventional apoptotic stimuli actinomycin D and tunicamycin, suggesting
that PON2/C12 interaction induces a novel form of apoptosis distinct from that
evoked by classical apoptotic stimuli (8) .
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Figure 3.13 PON2 is required in C12 cytotoxicity in human lung tumor
cells.
(A) PON2 expression in A549 cells was stably reduced by shRNA. The
expression levels of PON2 were determined by western blot. (B) C12 induced
less cell death in A549 cells with reduced PON2 expression than in control
vector cells. Cell death was assessed after 32 hour incubation. (C) Upon
treatment with different doses of C12 for 32 hours, less caspase-3/7 activation
was detected in cells with reduced PON2 expression than control vector cells.
(D) Stable reduction of PON2 expression in NCI-H1299 cells was evaluated by
western blot. (E) C12 induced less cell death in NCI-H1299 cells with reduced
PON2 following 24-hour treatment. (F) Less apoptosis was detected in NCIH1299 cells with reduced PON2 expression than control vector cells induced by
C12. All data shown are mean ± standard deviation of three independent
experiments. Asterisks indicate P values of ˂ 0.05 (*) or ˂ 0.01 (**) by
Student’s unpaired t test.
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3.14. Murine PON2 sensitizes human lung tumor cells with reduced
endogenous PON2 expression to C12.
To validate the role of PON2 in mediating C12-induced apoptosis, we stably
overexpressed murine PON2 cDNA in A549 cells deficient in PON2 expression
by retroviral infection (Figure 3.14A). Upon treatment with C12, we observed
more cell death and caspase-3/7 activation in PON2-deficient A549 cells
overexpressing murine PON2 compared to vector control and parental cells
(Figure 3.14B). Similarly, stable overexpression of murine PON3 in PON2knockdown NCI-H1299 cells was confirmed by western blot (Figure 3.14C). We
found that C12 induced more cell death and elicited higher caspase-3/7
activation in PON2-knockdown NCI-H1299 cells expressing mouse (Figure
3.14D).
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Figure 3.14 Murine PON2 sensitizes human lung tumor cells with reduced
endogenous PON2 expression to C12. (A) Murine PON2 cDNA was stably
overexpressed in A549 cells with reduced PON2 expression by retroviral
infection. Expression levels of PON2 were determined by western blot. (B-C) After
treating with different doses of C12 for 24 hours, more cell death (B) and
caspase-3/7 activation (C) were detected in PON2-knockdown A549 cells with
increased mouse PON2 expression comparing to vector control and parental
cells. (D) Stable overexpression of murine PON3 in PON2-knockdown NCI-H1299
cells was examined by western blot. (E-F) C12 induced more cell death (E) and
caspase-3/7 activation (F) in PON2-knockdown NCI-H1299 cells expressing
mouse PON2 after 24 hours treatment. All data shown are mean ± standard
deviation of three independent experiments. Asterisks indicate P values of ˂ 0.05
(*) or ˂ 0.01 (**) by Student’s unpaired t test.
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3.15. PON2 is essential for C12-triggered cell death in HEK-293T and HBE
cells.
To further explore the involvement of PON2 in apoptotic signaling in nontransformed cells, endogenous PON2 expression was stably reduced in
Human Embryonic Kidney-293T (HEK-293T) cells, whose viability was
assessed upon treatment with C12 (Figure 3.15A-B). Reducing PON2
expression in HEK-293 cells enabled cells resistant to C12. Furthermore, we
stably decreased PON2 expression in immortalized human bronchial epithelial
(HBE) cells (89) and measured cell viability upon C12 exposure (Figure 3.15CD). Reducing PON2 expression in HBE cells de-sensitized cells to C12.
Overall, these data provide evidence that PON2 plays a similar role in
apoptotic signaling in both transformed and non-transformed cells.
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Figure 3.15 PON2 is essential for C12-triggered cell death in HEK-293T and
HBE cells. (A) PON2 expression was stably reduced in HEK-293Tcells. (B)
The viability of HEK-293Tcells was measured 24 hours after C12 treatment. (C)
Stable decrease of PON2 expression in human bronchial epithelial (HBE) cells
was determined by western blot. (D)The viability of HBE was evaluated 24
hours following C12 exposure. Mean ± standard deviation for three
independent experiments are shown. For all the data, *, P < 0.05, Student’s
unpaired t test.
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3.16. PON2 is essential for human lung tumor cell proliferation but not nontransformed cell proliferation.
During the process of generating A549 and NCI-H1299 cells lacking PON2
expression, we observed that those cells proliferated much slower than their
vector control counterparts. To determine whether or not PON2 is essential for
human lung tumor cell proliferation, we measured the proliferation of A549 cells
and NCI-H1299 expressing PON2 shRNA or the empty vector control. We
found that proliferation of NCI-H1299 and A549 cells with reduced PON2
expression was slower compared to that of their empty vector expressing
counterparts (Figure 3.16A-B), implicating a role of PON2 in lung tumor cell
proliferation. To determine whether or not PON2 is involved in the proliferation
of non-transformed cells, we measured the proliferation of HEK-293T and HBE
expressing PON2 shRNA or the empty vector control. It was found that HEK293T and HBE cells lacking PON2 expression grew at the same rate as their
counterparts expressing the empty vector (Figure 3.16C-D), indicating that
PON2 is not involved in non-transformed cell proliferation. Overall, these data
indicate that PON2 mediates apoptosis independently of its function to
modulate cell proliferation.

56

Figure 3.16 PON2 is essential for human lung tumor cell proliferation but
not non-transformed cell proliferation. The proliferation of A549 cells (A),
NCI-H1299 cells (B), HEK-293T cells (C) and HBE cells (D) expressing PON2
shRNA or the empty vector control was measured. Proliferation of NCI-H1299
and A549 cells with reduced PON2 expression was slower compared with their
counterparts expressing the empty vector. HEK-293T cells (C) and HBE cells
with reduced PON2 expression proliferated at the same rate as their vector
control counterparts. All data shown are mean ± standard deviation of three
independent experiments. Asterisks indicate P values of ˂ 0.05 (*) by Student’s
unpaired t test.
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3.17. Deficiency in PON2 expression induces G1 cell cycle arrest of A549 cells.
To investigate the effects of deficient PON2 expression, we performed cell
cycle analysis to determine the cell cycle profile of A549 cells expressing
PON2 shRNA or the empty vector. We found that deficiency in PON2
expression induces cell cycle arrest at G1 phase in A549 cells (Figure 3.17).
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Figure 3.17. Deficiency in PON2 expression induces G1 cell cycle arrest of
A549 cells. (A) Cell cycle profiles of A549 cells expressing PON2 shRNA or the
empty vector control were determined. (B) Summary of the data shown in (A).
Reducing PON2 expression caused higher percentage of the cells in G1 phase of
cell cycle. All data shown are mean ± standard deviation of three independent
experiments. Asterisks indicate P values of ˂ 0.01 (**) by Student’s unpaired t test.
“ns”, no significance.
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CHAPTER 4: DISCUSSION
The quorum-sensing molecule C12 evokes apoptosis in a variety of mammalian
cells (62,65,68,90). Several signaling pathways leading to apoptosis have been
associated with C12 cytotoxicity. In addition to the activation of the intrinsic
apoptosis pathway, C12 is also shown to induce caspase-8 activation,
suggesting a role of the extrinsic apoptosis cascade in C12-induced apoptosis (9).
The interplay between these pathways and the functions of key molecules
involved were still unclear. In this study using cells deficient in one or more
caspases, we present evidence that caspase-3/7 and caspase-9 but not
caspase-8 are essential for C12-induced apoptotic cell death (Figures 3.1-3.2),
indicating that C12 selectively triggers the mitochondria-dependent intrinsic
apoptotic pathway. Previously reported C12-caused caspase-8 activation; in
addition to the events associated with activating a plasma membrane receptor
(e.g. TNF receptor), are likely secondary responses to MOMP. The dispensable
roles of both “initiator” caspase (e.g. caspase-9) and “effector” caspase (e.g.
caspase-3/7) in C12-indcued MOMP demonstrate that C12 may directly damage
mitochondria without the involvement of other pathways triggering caspase
activation.

Consistent with its ability to induce depolarization of ∆mito within 20 minutes
(Figures 3.2 and 3.5), amphipathic C12 molecules assemble permeation
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channels in phospholipid membranes without any proteins (Figure 3.8). The
characteristics of channels formed by C12 are similar to those of ceramide
(85,85). Ceramide has been demonstrated to suppress tumors through inhibiting
tumor cell proliferation, triggering apoptosis, autophagy and/or senescence
(85,86). Ceramide-induced apoptosis signaling is modulated by both anti- and
pro-apoptotic Bcl-2 proteins (91,92). In agreement with their functions in
apoptotic signaling, Bcl-2 proteins also regulate ceramide channels in vitro
(93,94). It appears that C12 and ceramide evoke distinct apoptotic signaling with
C12-triggered apoptotic responses independent of both anti- and pro-apoptotic
Bcl-2 proteins in non-transformed as well as tumor cells.

Several signaling pathways linked to apoptosis initiation, including JAK/STAT
pathway (66), MAPK and eIF2 pathways (60), and ER stress pathway (63,65),
have been implicated in C12-evoked cell death. These apoptosis-associated
signaling pathways are normally involved in multiple steps of signal transduction,
and the biological events reflective of these signaling cascades are observed
hours following C12 incubation. In contrast, depolarization of ∆mito, the earliest
step of MOMP (6), is always detected within minutes upon C12 exposure and
reaches its maximal levels in 20 minutes as reported here (Figures 3.2 and 3.5)
and in our earlier studies (8,9). Thus, it appears that activation of these signaling
pathways is secondary to MOMP initiation in C12-triggered apoptosis cascade. It
is conceivable that C12 or its metabolite(s) acts directly on mitochondria to
permeabilize them. The in vitro studies in this paper support the notion that C12

61

might directly assemble permeation channels on mitochondria, leading to
cytochrome c release, apoptotic cascade activation, and ultimately apoptosis.

Many neoplastic cells show an increased ratio of anti-apoptotic to pro-apoptotic
Bcl-2 proteins, which enables them to survive even under the conditions that
would normally initiate apoptotic signaling (95). An emerging strategy for cancer
therapy is to overcome the resistance to apoptosis caused by aberrant Bcl-2
signaling in tumor cells (96,97). Recently, several small molecules triggering
apoptosis independent of either pro- or anti-apoptotic Bcl-2 proteins have been
identified as potential anti-tumor drugs. Among them, the pentacyclic triterpenoid
betulinic acid induces Bax/Bak-independent MOMP and subsequent apoptosis
(98,99). Unlike C12, cytotoxic effects of betulinic acid are influenced by Bcl-2
overexpression and it is ineffective against epithelial tumors. Similarly, Bax/Bak
is also nonessential in apoptotic signaling induced by chelerythrine (100) or
titanium dioxide (TiO2) (101). The polyphenolic compound gossypol evokes
Bax/Bak-independent apoptosis and inhibits Bcl-2-overexpressing human B
lymphoblast tumor growth in nude mice (102). Furthermore, Bcl-2 expression
fails to influence human tumor cell apoptosis induced by the antibiotic agent
Tetrocarcin-A (103,104). Compared with those molecules, C12 is the first small
molecule compound, to the best of our knowledge, inducing human tumor cell
apoptosis in vitro as well as blocking tumor growth in vivo independent of both
pro- and anti-apoptotic Bcl-2 proteins.
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The apoptosis cascade induced by C12 in tumor cells is unique, evident by its
rapid pro-apoptotic effects, such as depolarizing mitochondrial membrane
potential within minutes (Figures 3.10 and 3.11), releasing cytochrome c into the
cytosol and maximally activating caspases. These distinctive pro-apoptotic
features of C12 have not been observed in any other apoptosis paradigms of
cancer cells, which might be attributed to the ability of C12 or its derivatives
generated in tumor cells to directly permeabilize mitochondria without the
involvement of pro- and anti-apoptotic Bcl-2 proteins. This study also shows that
endogenous PON2 is essential for C12‘s cytotoxicity in human lung tumor cells
(Figure 3.13), which is consistent with our previous observation of PON2
overexpression in non-transformed fibroblasts and HEK293T cells (9).
It has been reported that lung tumor cells are resistant to conventional
therapeutic drugs partially due to enhanced expression of PON2, which is
thought to be associated with anti-oxidant activities of PON2 (78,79). Data
presented in Figure 3.13 show decreased killing of A549 and NCI-H1299 cells
with shRNA for PON2; which is consistent with previous results (9). Additionally,
data in Figure 3.13 indicate that killing activities of C12 on lung tumor cells is
mediated through PON2. Thus, it is conceivable that C12 or compounds derived
from C12 could trigger rapid and Bcl-2 protein-independent apoptosis in lung
tumors that are resistant to traditional chemotherapeutic drugs, whereas normal
tissues are spared due to their lower PON2 expression.
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PON2 is known to associate with the mitochondrial electron transport chain
Complex III component coenzyme Q10 (CoQ10), and it is optimally positioned
with appropriate enzymatic activity to cleave oxidized mitochondrial lipids
(73,105). One possibility is that enhanced PON2 expression in tumor cells
functions by interacting with CoQ10, leading to increased mitochondrial electron
transport, and subsequent mitochondrial bioenergetics, which generate enough
ATP and metabolites to sustain the rapid proliferation of lung tumor cells.
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CHAPTER 5: CONCLUSION
Overall, our study reveals that C12 induces a unique mitochondrial apoptotic
signaling pathway, in which C12 or C12 metabolite(s) acts on mitochondria as a
mitolytic molecule to permeabilize mitochondria, leading to activation of
apoptosis signaling independent of both pro- and anti-apoptotic Bcl-2 proteins.
These properties of C12 enable it inhibit tumor growth as a single agent
regardless of Bcl-2 protein expression in tumors, making it an ideal candidate of
a lead compound for novel therapeutic agents for cancer. Further to this, our
studies indicate that PON2 expression in non-small cell lung carcinoma cells is
essential for their rapid proliferation. Therefore, C12 is an ideal candidate of a
lead compound for novel therapeutic agents for cancer.
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APPENDIX: LIST OF ABBREVIATIONS
5-FU

5-Fluorouracil

Apaf-1

Apoptotic Protease Factor 1

BH

Bcl-2 homolog

C12

N-(3-oxododecanoyl)-homoserine lactone

COQ10

Coenzyme Q10

DISC

Death Inducing Signaling Complex

FADD

Fas Associated Death Domain

FasL

Fas Ligand

FBS

Fetal Bovine Serum

IAPs

Inhibitor of Apoptosis Proteins

LLC

Lewis Lung Carcinoma

MEFs

Mouse Embryonic Fibroblasts

MIPs

Maximum Intensity Projections

MOMP

Mitochondrial Outer Membrane Permeabilization

NHBE

Human Bronchi/Tracheal Epithelial Cells

NSCLC

Non-Small Cell Lung Carcinoma

OMM

Outer Mitochondrial Membrane

PBS

Phosphate Buffered Saline

PI

Propidium Iodide

PON2

Paraoxonase 2
72

ROIS

Regions of Interest

TLR4

Toll-Like Receptor 4

TNF

Tumor Necrosis Factor

TNFR

Tumor Necrosis Factor Receptor

TNFR1

Tumor Necrosis Factor Receptor 1

TRAIL

TNF-Related Apoptosis Inducing Ligand

WT

Wild Type
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